Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
| العنوان: | Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review |
|---|---|
| المؤلفون: | Yusuke Chihara, Yoshiko Kaneko, Yoshie Morimoto, Junji Uchino, Takayuki Shimamoto, Tadaaki Yamada, Masahiro Iwasaku, Koichi Takayama, Keisuke Onoi |
| المصدر: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 9, Iss 1362, p 1362 (2020) |
| بيانات النشر: | MDPI AG, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Durvalumab, medicine.medical_treatment, lcsh:Medicine, Review, Pembrolizumab, Treatment of lung cancer, immune checkpoint inhibitors, 03 medical and health sciences, 0302 clinical medicine, Atezolizumab, PD-1, Medicine, 030212 general & internal medicine, Lung cancer, business.industry, lcsh:R, General Medicine, medicine.disease, Immune checkpoint, Radiation therapy, non-small-cell lung cancer, 030220 oncology & carcinogenesis, Cancer research, biomarker, Nivolumab, business |
| الوصف: | The treatment of lung cancer has changed drastically in recent years owing to the advent of immune checkpoint inhibitors (ICIs). A 1992 study reported that programmed cell death-1 (PD-1), an immune checkpoint molecule, is upregulated during the induction of T cell death. Since then, various immunoregulatory mechanisms involving PD-1 have been clarified, and the successful use of PD-1 blockers in anticancer therapy eventually led to the development of the current generation of ICIs. Nivolumab was the first ICI approved for treating lung cancer in 2014. Since then, various ICIs such as pembrolizumab, atezolizumab, and durvalumab have been successively introduced into clinical medicine and have shown remarkable efficacy. The introduction of ICIs constituted a major advancement in lung cancer treatment, but disease prognosis continues to remain low. Therefore, new molecular-targeted therapies coupled with existing anticancer drugs and radiotherapy have recently been explored. This review encompasses the current status, challenges, and future perspectives of ICI treatment in lung cancer. |
| تدمد: | 2077-0383 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02eb17ad87c963a97ce06afa29697766Test https://doi.org/10.3390/jcm9051362Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....02eb17ad87c963a97ce06afa29697766 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20770383 |
|---|